A panel of researchers from the European Combined Highly Active Anti-Retroviral Microbicides (CHAARM) Consortium has discovered in a recent study that a vaginal microbicide gel is promising for preventing the spread of HIV/AIDS.
As per a recent report, the gel, which is easy-to-apply, can act as a robust preventative agent when it comes to sexual transmission of HIV. Dereuddre-Bosquet, lead researcher from CHAARM, says the key ingredient of the gel is such that it does not allow the virus to infect one's body cells.
Peptides named "miniCD4s" were engineered by the team, which could further be presented as a trap that could tie up the life-threatening bug. The peptides were chosen to be created for the reason that these mimic HIV-used CD4 receptor to make entry into the body's immune cells.
It was found that HIV entry was being blocked by the miniCD4s into a dish and tissue models' isolated cells. These cells mimicked mucous membranes that make for the virus entry.
It is thus that these miniCD4s were then formulated at 0.3% in a gel. Six female cynomolgus macaques monkeys got the same applied for an hour, who later received the same in high dose. It was noted that they were fully protected and the virus was not anywhere around.
- Finally a $7 Billion Settlement for Citigroup
- Discussions In Progress for Merger of Tobacco Businesses: Reynolds to Acquire Lorillard
- Amazon Seeks Permission to Fly Drones for Delivery of Packages from FAA
- Wells Fargo Reports a Profit
- Abbott hits JV deal with Fonterra to operate diary farms in China